Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…Abstract Number: 1222 • 2018 ACR/ARHP Annual Meeting
Suboptimal Immunization Coverage Among Rheumatology Patients in Routine Clinical Care
Background/Purpose: Vaccine-preventable infections pose an increased risk of infection and complications in patients with rheumatic diseases. While recommendations highlight the importance of vaccination in this…Abstract Number: 1223 • 2018 ACR/ARHP Annual Meeting
Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis, an autoimmune disease affecting ~1% of the population, have an increased risk of infection. Interestingly, data are mixed for response…Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting
High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment
Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…Abstract Number: 1225 • 2018 ACR/ARHP Annual Meeting
Screening for Acquired Latent Tuberculosis in Patients with Rheumatoid Arthritis(RA) on Anti-Tnfα Therapy (TNF-I) in Southern California
Background/Purpose: There is increased risk of tuberculosis in patients treated with TNF-I. ACR guidelines recommend annual screening for latent tuberculosis infection(LTBI) in RA patients with…Abstract Number: 1226 • 2018 ACR/ARHP Annual Meeting
Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis
Background/Purpose: Biologics are widely used and effective treatments for rheumatoid arthritis (RA), but generally biologics are avoided when patients have active infections on the day…Abstract Number: 1227 • 2018 ACR/ARHP Annual Meeting
Indicator Opportunistic Infections after Biological Treatment in Rheumatoid Arthritis, 10 Years Follow up in Clinical Practice
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) may be associated with opportunistic infections. Our purposes were to describe their incidence in Rheumatoid Arthritis (RA) taking bDMARDs,…Abstract Number: 1228 • 2018 ACR/ARHP Annual Meeting
Spine Immobilization and Neurological Complications in Vertebral Osteomyelitis: Results from a Multicenter Prospective Observational Study
Background/Purpose: In a previous work, we showed that neurological complication can occur in up to 40% of patients with vertebral osteomyelitis (VO). Bed rest and…Abstract Number: 1229 • 2018 ACR/ARHP Annual Meeting
Diagnosing Prosthetic Joint Infections in Patients with Inflammatory Arthritis
Background/Purpose: Patients with inflammatory arthritis (IA) are at increased risk of prosthetic joint infections, yet differentiating between septic and aseptic failure is a challenge in…Abstract Number: 1230 • 2018 ACR/ARHP Annual Meeting
Invasive Fungal Infection with Cryptococcal Meningitis in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder with immunodeficiency associated with the disease itself and immunosuppressive treatment. Infections are very frequent events…Abstract Number: 1231 • 2018 ACR/ARHP Annual Meeting
Pyogenic Vertebral Osteomyelitis: Outcome Variables Analysis in a 116 Patients Cohort at a Tertiary Hospital during the Last 8 YEARS
Background/Purpose: Vertebral Osteomyelitis is an infectious disease of the vertebral body which could involve the intervertebral space (spondylodiscitis). Early diagnosis and treatment are essential in…Abstract Number: 1232 • 2018 ACR/ARHP Annual Meeting
Synovial Fluid Profile in Neutropenic Patients with Septic Arthritis
Background/Purpose: In patients with septic arthritis, the white blood cell count in the synovial fluid is classically >50,000 cells/μL. While a microorganism must be identified…Abstract Number: 1233 • 2018 ACR/ARHP Annual Meeting
Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study
Background/Purpose: Rituximab (RTX) is a chimeric monoclonal antibody approved for the treatment rheumatoid arthritis (RA) patients who failed to respond to tumor necrosis factor inhibitors.…Abstract Number: 1234 • 2018 ACR/ARHP Annual Meeting
Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of…Abstract Number: 1235 • 2018 ACR/ARHP Annual Meeting
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
Background/Purpose: Although use of glucocorticoid increases the risk of tuberculosis (TB) disease, there has been few studies investigating its incidence and risk/benefit assessment of the…
ACR Meeting Abstracts